Navigation Links
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
Date:10/31/2011

ira announced that it had entered into agreements with Quintiles Commercial US, Inc. (Quintiles) and Integrated Commercialization Services, Inc. (ICS) to support the anticipated launch of EXPAREL.
  • Presented at the 38th Annual Meeting & Exposition of the Controlled Release Society (CRS). In August 2011, Pacira presented new preclinical data evaluating the safety of DepoFoam, the Pacira proprietary, extended-release drug delivery technology, during two podium sessions at CRS in National Harbor, Md.

  • Financial Highlights

  • Net loss for the third quarter ended September 30, 2011 was $9.5 million, or $0.55 per share (based on 17.2 million weighted average shares outstanding), compared with $7.9 million, or $13.77 per share, for the quarter ended September 30, 2010 (based on 0.6 million weighted average shares outstanding). The difference in the number of weighted average shares outstanding primarily resulted from the Pacira initial public offering (IPO) in February 2011, as well as the conversion of all preferred stock and the principal and accrued interest on certain notes into common stock upon closing of the IPO.
  • Total revenues for the quarter ended September 30, 2011 were $4.0 million compared with $4.5 million for the third quarter of 2010. The decrease was primarily attributable to a $1.1 million decline in supply revenue which reflects fewer lot sales to Pacira's commercial partners. This was offset by a $0.6 million increase in collaborative licensing and development revenue which was principally driven by activities performed under the license agreement Pacira has with Novo Nordisk that was executed in the first quarter of 2011.
  • Total operating expenses for the quarter ended September 30, 2011 were $12.7 million compared with $11.0 million for the same period of 2010. The $1.7 million increase was primarily attributable to expenses related to pre-commercialization activities performed in anticipation o
    '/>"/>

  • SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
    8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
    9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
    10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
    11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
    (Date:9/2/2015)... 2, 2015 Research and Markets ( ... "Medical Device Studies: Clinical Evidence (London, UK ... offering. This course has been ... gathering clinical evidence required for medical devices and ... all medical devices and the emphasis on high ...
    (Date:9/2/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... Officer of Neurocrine Biosciences, will be presenting at the ... City . The live presentation takes ... PT).  The presentation will be webcast and may be ... Listeners are encouraged to visit the ...
    Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
    ... 2 HART Health, a national manufacturer and distributor ... service division of Synergy Logistics, a Seattle-based first aid ... new franchise system. Synergy Logistics, Inc. had ... delivery service to mid-sized Seattle businesses since the early ...
    ... Results from studies related to ... lead developmental product candidate, fidaxomicin, will ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ... Exhibition Center in Boston on September 12-15, 2010. ...
    Cached Medicine Technology:First Aid Supplier HART Health Acquires Competitor and Continues Expansion 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 3
    (Date:9/2/2015)... ... September 02, 2015 , ... ... large stream of mixed documents that include EOBs, payments, and payment related documents. ... the data needed to reconcile their billing, with one efficient process and interface,“ ...
    (Date:9/2/2015)... Pittsburgh, PA (PRWEB) , ... September 02, 2015 ... ... the Health Sciences clinical and academic partnership has earned international recognition as a ... rare genetic disorder that can cause sudden, catastrophic internal bleeding and stroke. ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... largest and fastest-growing interim clinical staffing companies, has completed a recapitalization with ... , BPOC and Heritage Group each offer extensive expertise and ...
    (Date:9/2/2015)... Kansas City, KS (PRWEB) , ... September 02, 2015 , ... ... recently opened its newest office in Kansas – its Johnson County location. ... backgrounds in healthcare. Mike has a registered nurse background and spent over 20 years ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be ... risk of getting ovarian cancer in her lifetime is approximately 1 in 75. This ... ovarian cancer, and 14,000 will die. , There is no test to detect ...
    Breaking Medicine News(10 mins):Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3
    ... , , WASHINGTON, July 24 ... today in support of the minimum wage increase from $6.55 an hour ... minimum wage increase is an important step in recovering our economy, rebuilding ... it is only one of three prongs necessary to create a real ...
    ... common, but labeling is not required, report states , ... "enhance" uncooked meat and poultry can pose serious health ... Many fresh meat and poultry products are injected with ... not required to be listed on food labels, according ...
    ... , , CLEVELAND, July 24 /PRNewswire/ ... access for the uninsured and underinsured to a wide range of health ... 25 and 26, at the W.O. Walker Center, 10524 Euclid Ave. The ... provide 1100 medical, 300 vision and 200 dental patient visits. Appointments ...
    ... , CHICAGO, July 24 ... in designing and manufacturing portable rechargeable systems, today ... single-output power supplies. The new 350-watt series, designed ... delivers an industry-leading converter efficiency of up to ...
    ... WESTBROOK, Maine, July 24 IDEXX Laboratories, Inc. (Nasdaq: ... second quarter of 2009 were $265.7 million compared to $280.6 ... as defined below, was 5%. Earnings per diluted share ("EPS") ... to $0.63 for the same period in the prior year. ...
    ... ... Texans find affordable, direct access to medical lab testing through Any Lab Test Now®. , ... Plano, TX (PRWEB) July 24, 2009 -- This ... company has found its niche. Opened December 2008, Any Lab Test Now® in ...
    Cached Medicine News:Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:Convection Cooled 350-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards 2Health News:IDEXX Laboratories Announces Second Quarter Results 2Health News:IDEXX Laboratories Announces Second Quarter Results 3Health News:IDEXX Laboratories Announces Second Quarter Results 4Health News:IDEXX Laboratories Announces Second Quarter Results 5Health News:IDEXX Laboratories Announces Second Quarter Results 6Health News:IDEXX Laboratories Announces Second Quarter Results 7Health News:IDEXX Laboratories Announces Second Quarter Results 8Health News:IDEXX Laboratories Announces Second Quarter Results 9Health News:IDEXX Laboratories Announces Second Quarter Results 10Health News:IDEXX Laboratories Announces Second Quarter Results 11Health News:IDEXX Laboratories Announces Second Quarter Results 12Health News:IDEXX Laboratories Announces Second Quarter Results 13Health News:IDEXX Laboratories Announces Second Quarter Results 14Health News:IDEXX Laboratories Announces Second Quarter Results 15Health News:IDEXX Laboratories Announces Second Quarter Results 16Health News:IDEXX Laboratories Announces Second Quarter Results 17Health News:IDEXX Laboratories Announces Second Quarter Results 18Health News:IDEXX Laboratories Announces Second Quarter Results 19Health News:IDEXX Laboratories Announces Second Quarter Results 20Health News:IDEXX Laboratories Announces Second Quarter Results 21Health News:IDEXX Laboratories Announces Second Quarter Results 22Health News:Cost-Conscious Texans Find Relief with Direct Access Lab Testing 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: